<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="73750">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01752543</url>
  </required_header>
  <id_info>
    <org_study_id>H-3-2012-139</org_study_id>
    <nct_id>NCT01752543</nct_id>
  </id_info>
  <brief_title>Effects on Exercise Hemodynamics of Vasopressin Blockade by Conivaptan Infusion in Heart Failure Patients</brief_title>
  <official_title>Effects on Exercise Hemodynamics of Vasopressin Blockade by Conivaptan Infusion in Heart Failure Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Finn Gustafsson</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <authority>Denmark: The Regional Committee on Biomedical Research Ethics</authority>
    <authority>Denmark: Danish Medicines Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the present study is to evaluate the effects of a blockade of the vasopressin
      system and central hemodynamic system in heart failure (HF) patients during physical
      exercise. The significance of the vasopressin system during physical exercise is unclear. If
      vasopressin is a significant regulator of exercise hemodynamics in HF, strategies to
      intervene against activation of the V1A-receptor might be expected to improve HF symptoms
      and possibly outcome.

      The potential effects of the central hemodynamic system will be evaluated with a Swan-Ganz
      catheter. Echocardiography will be performed at rest and during submaximal working capacity
      before and during the infusion of a vasopressin receptor antagonist (conivaptan) or placebo.
      Cardiac output will be measured by thermodilution. The exercise test will be performed at 50
      % of VO2 max and hemodynamic and echocardiographic measurements will be collected. The
      exercise test will be performed on a supine multistage bicycle.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">November 2014</completion_date>
  <primary_completion_date type="Anticipated">November 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The joint endpoint of change in pulmonary capillary wedge pressure (PCWP) and cardiac output (CO) at the submaximal exercise intensity of 50 % of the maximal exercise capacity</measure>
    <time_frame>1 day</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiac index (CI) during submaximal exercise from rest to submaximal exercise</measure>
    <time_frame>1 day</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary and systemic vascular resistance from rest to submaximal exercise</measure>
    <time_frame>1 day</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricular end diastolic diameter during exercise from rest to submaximal exercise</measure>
    <time_frame>1 day</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in mean pulmonary artery pressure (mPAP) from rest to submaximal exercise</measure>
    <time_frame>1 day</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in BNP, MR-ANP and copeptin from rest to submaximal exercise</measure>
    <time_frame>1 day</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Conivaptan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10 patients will be randomized to conivaptan treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dextrose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>10 patients will receive placebo treatment (dextrose)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Conivaptan</intervention_name>
    <description>Conivaptan treatment: 20 mg bolus followed by infusion of 2 mg/hour</description>
    <arm_group_label>Conivaptan</arm_group_label>
    <other_name>Vaprisol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (Dextrose)</intervention_name>
    <arm_group_label>Dextrose</arm_group_label>
    <other_name>5 % dextrose</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years

          -  Left ventricular ejection fraction (LVEF) &lt; 45 % on the baseline echocardiography.

          -  Treatment with beta-blockers and angiotensin-converting-enzyme (ACE) inhibitors for
             at least 1 month as tolerated

          -  New York Heart Association (NYHA) Functional Class II-III

          -  Given informed consent

          -  Women, who have not yet entered menopause (defined as no menstrual bleeding in the
             last 12 months), will provide a negative urine HCG before entering the study

        Exclusion Criteria:

          -  Signs of symptomatic or ongoing myocardial ischemia

          -  Known non-revascularized coronary disease

          -  Presence of hypovolemic hyponatremia (P-Na+ &lt;130 mmol/l and clinical signs of volume
             depletion or dehydration as judged by investigator).

          -  Hypernatraemia (P-Na+) &gt; 145 mmol/L

          -  Chronic obstructive pulmonary disease (FEV1/FVC &lt; 70 % and/or 30 % &gt; FEV1 &lt; 50 %)

          -  Supine systolic blood pressure &lt; 85 mmHg

          -  Significant orthostatic hypotension

          -  Standing blood pressure &lt; 80 mmHg or a blood pressure drop &gt; 20 mmHg when changing
             from a supine to a standing position

          -  Uncontrolled hypertension evaluated by the investigator

          -  Uncontrolled cardiac arrhythmias evaluated by the investigator

          -  Untreated serious hypothyroidism

          -  Adrenal insufficiency

          -  Poor echocardiographic window

          -  Inability to perform exercise testing

          -  Permanent atrial fibrillation or atrial fluttering

          -  Planned coronary by-pass surgery

          -  Moderate hepatic impairment (ALAT/ASAT &gt; 3 UNL)

          -  Presence of other diseases affecting treatment with conivaptan or the evaluation of
             safety as evaluated by the investigator

          -  Severely decreased kidney function (eGFR &lt; 20 mL/min)

          -  Serum K+&lt; 3.5 or &gt; 5.5 mmol/L

          -  Known conivaptan intolerability

          -  Corn allergy

          -  Dextrose Allergy

          -  Treatment with potent CYP3A-inhibitors (ketoconazole, itraconazole, clarithromycin,
             ritonavir, indinavir)

          -  Treatment with arginine vasopressin, oxytocin, desmopressin and other medications for
             the treatment of hyponatremia (lithium salts, urea and demeclocycline)

          -  Warfarin treatment

          -  Presence of infection or active bleeding
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Louise Balling, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Finn Gustafsson, MD, PhD, DMSci</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Finn Gustafsson, MD, PhD, DMSci</last_name>
    <phone>004535459743</phone>
    <email>finn.gustafsson@regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Louise Balling, MD</last_name>
    <phone>004523451679</phone>
    <email>louise.balling@dadlnet.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Cardiology, Copenhagen University Hospital, Rigshospital</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Finn Gustafsson, MD, PhD, DMSci</last_name>
      <phone>004535459743</phone>
      <email>finn.gustafsson@regionh.dk</email>
    </contact>
    <contact_backup>
      <last_name>Louise Balling, MD</last_name>
      <phone>004523451679</phone>
      <email>louise.balling@dadlnet.dk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <lastchanged_date>December 14, 2012</lastchanged_date>
  <firstreceived_date>December 12, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Finn Gustafsson</investigator_full_name>
    <investigator_title>Staff Cardiologist, MD, Phd, DMSci</investigator_title>
  </responsible_party>
  <keyword>Vasopressin</keyword>
  <keyword>Exercise capacity</keyword>
  <keyword>Conivaptan</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vasopressins</mesh_term>
    <mesh_term>Arginine Vasopressin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
